TUMOR BIOLOGY AND MICROENVIRONMENT (TBM) ? ABSTRACT The Tumor Biology and Microenvironment (TBM) Program is a translational science program that aims to discover the cellular and molecular determinants that drive the initiation and progression of cancers through interactions with their microenvironments and develop and test innovative diagnostic and treatment strategies. This highly integrated Program includes 37 members from 13 departments and 4 schools at Wayne State University. TBM Program members, who conduct basic, preclinical, and clinical research, receive $4,468,183 in peer reviewed, cancer-related grant support, of which $1,943,419 is from the NCI. The TBM Program is organized along three major themes. The goal of the first theme is to explore biological processes that mediate the phenotypical plasticity, proliferation, and survival of tumor cells. Translational research is conducted to evaluate the potential clinical application of these molecular determinants as tumor markers and/or therapeutic targets. The second theme investigates mechanisms that enable tumor cells to overcome external barriers during invasion and metastasis. Our investigators assess the importance of factors that control extracellular proteolysis and signaling mechanisms that are being used by tumor cells to adapt to and subvert the microenvironment at primary and metastatic sites. The objective of the third theme is to develop new strategies to engage the immune system as powerful defenses against cancer. Research activities include the development of immune modulators and novel vehicles to optimally deliver immunotherapeutics, as well as the use of state-of-the art imaging modalities for monitoring the success to tumor immunotherapy. The TBM Program is led by Dr. Kay-Uwe Wagner as Program Leader and Dr. Asfar Azmi as Program Co-Leader. The Leader and Co-Leader are new since the last competitive renewal. All members of the TBM Program actively collaborate with members of the MI, MT, and PSDR Programs at KCI. Of the 484 manuscripts published between December 2015 and November 2019, 41% and 44% were intra- and inter-programmatic, respectively, and 61% were multi-institutional collaborations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA022453-39
Application #
10088976
Study Section
Special Emphasis Panel (ZCA1)
Project Start
1997-08-08
Project End
2025-11-30
Budget Start
2020-12-15
Budget End
2021-11-30
Support Year
39
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Shah, Seema; Brock, Ethan J; Jackson, Ryan M et al. (2018) Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia 20:951-963
An, Mingrui; Wu, Jing; Zhu, Jianhui et al. (2018) Comparison of an Optimized Ultracentrifugation Method versus Size-Exclusion Chromatography for Isolation of Exosomes from Human Serum. J Proteome Res 17:3599-3605
Yu, Chunsong; An, Myunggi; Jones, Evan et al. (2018) Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity. Pharm Res 35:56
Kariburyo, Furaha; Wang, Yuexi; Cheng, I-Ning Elaine et al. (2018) Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study. BMC Urol 18:55
Thakur, Manish K; Heilbrun, Lance; Dobson, Kimberlee et al. (2018) Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. Clin Genitourin Cancer 16:e695-e703
Feldmann, Daniel P; Cheng, Yilong; Kandil, Rima et al. (2018) In vitro and in vivo delivery of siRNA via VIPER polymer system to lung cells. J Control Release 276:50-58
Vaishampayan, Ulka (2018) Advantages and Adversities of the Weighted Toxicity Score. Clin Cancer Res 24:4918-4920
Wang, Zhaoxian; Sau, Samaresh; Alsaab, Hashem O et al. (2018) CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer. Nanomedicine 14:1441-1454
Ravindra, Manasa; Wilson, Mike R; Tong, Nian et al. (2018) Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor ? and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis. J Med Chem 61:4228-4248
Kim, Seongho; Wong, Weng Kee (2018) Extended two-stage adaptive designs with three target responses for phase II clinical trials. Stat Methods Med Res 27:3628-3642

Showing the most recent 10 out of 826 publications